XML 41 R34.htm IDEA: XBRL DOCUMENT
v3.24.2.u1

Loss Per Share (Tables) | 6 Months Ended
--- | ---
Jun. 30, 2024
Earnings Per Share [Abstract] |
Schedule of Weighted Average Number of Ordinary Shares Outstanding and The Effect of Dilutive Ordinary Share | Diluted loss per share is based on dividing the loss attributable for the year, adjusted for the effect of dilutive ordinary shares, by ordinary share equivalents, which includes the weighted average number of ordinary shares outstanding and the effect of dilutive ordinary share equivalents.
|  | Three Months Ended June 30, |  |  | Six Months Ended June 30, |
|  | 2024 |  |  | 2023 |  |  | 2024 |  |  | 2023 |
|  | ($'000, except share and per share amounts) |  |  | ($'000, except share and per share amounts) |  |  | ($'000, except share and per share amounts) |  |  | ($'000, except share and per share amounts) |
Net loss |  | $ | (12,255 | ) |  | $ | (1,751 | ) |  | $ | (21,208 | ) |  | $ | (13,827 | )
Net loss per share - basic and diluted |  | $ | (0.02 | ) |  | $ | (0.00 | ) |  | $ | (0.03 | ) |  | $ | (0.02 | )
Weighted-average number of shares used in computing net loss per share - basic and diluted |  |  | 711,770,804 |  |  |  | 628,421,064 |  |  |  | 706,407,371 |  |  |  | 626,185,695 |
Schedule of Potentially Dilutive Shares Were Not Included In The Calculation of Diluted Shares Outstanding. | The Company excluded the following potentially dilutive ordinary shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect:
|  | Six Months Ended June 30, |
|  | 2024 |  |  | 2023 |
Options |  |  | 73,698,315 |  |  |  | 64,289,090 |
RSUs |  |  | 2,640,115 |  |  |  | 2,738,750 |
PSUs |  |  | 2,676,300 |  |  |  | 6,690,750 |
DRSUs |  |  | 4,276,875 |  |  |  | 3,637,905 |
Convertible loan notes – Novartis |  |  | 16,308,364 |  |  |  | 15,000,137 |
Convertible loan notes – private placement |  |  | - |  |  |  | 24,279,659 |
Warrants to purchase ordinary shares |  |  | 7,539,129 |  |  |  | 7,539,129 |
AstraZeneca milestones potentially payable in equity |  |  | 1,349,692 |  |  |  | 1,349,692 |

X
- References No definition available. + Details
Name: | us-gaap_EarningsPerShareAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details
Name: | us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit). + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details
Name: | us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration